MDT

96.57

-0.29%↓

A

147.59

+0.46%↑

VEEV

223.95

-2.66%↓

HQY

86.11

+3.25%↑

PHR.US

16.35

0%↓

MDT

96.57

-0.29%↓

A

147.59

+0.46%↑

VEEV

223.95

-2.66%↓

HQY

86.11

+3.25%↑

PHR.US

16.35

0%↓

MDT

96.57

-0.29%↓

A

147.59

+0.46%↑

VEEV

223.95

-2.66%↓

HQY

86.11

+3.25%↑

PHR.US

16.35

0%↓

MDT

96.57

-0.29%↓

A

147.59

+0.46%↑

VEEV

223.95

-2.66%↓

HQY

86.11

+3.25%↑

PHR.US

16.35

0%↓

MDT

96.57

-0.29%↓

A

147.59

+0.46%↑

VEEV

223.95

-2.66%↓

HQY

86.11

+3.25%↑

PHR.US

16.35

0%↓

Search

TG Therapeutics Inc

Deschisă

SectorSănătate

29.81 8.4

Rezumat

Modificarea prețului

24h

Curent

Minim

27.55

Maxim

33.15

Indicatori cheie

By Trading Economics

Venit

363M

391M

Vânzări

21M

162M

P/E

Medie Sector

10.007

90.831

Marjă de profit

241.727

Angajați

374

EBITDA

-4.9M

33M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+42.62% upside

Dividende

By Dow Jones

Următoarele câștiguri

2 mar. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

-945M

4.4B

Deschiderea anterioară

21.41

Închiderea anterioară

29.81

Sentimentul știrilor

By Acuity

37%

63%

131 / 361 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Very Strong Bearish Evidence

TG Therapeutics Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

13 ian. 2026, 19:05 UTC

Principalele dinamici ale pieței

Travere Therapeutics Shares Fall After FDA Extends Filspari Review

13 ian. 2026, 23:41 UTC

Market Talk

Nikkei May Rise on Japan Election Hopes -- Market Talk

13 ian. 2026, 23:41 UTC

Market Talk

Global Equities Roundup: Market Talk

13 ian. 2026, 23:33 UTC

Market Talk

Gold Edges Higher, Supported by Ongoing Geopolitical Tensions -- Market Talk

13 ian. 2026, 23:13 UTC

Achiziții, Fuziuni, Preluări

JD Logistics Plans to Withdraw Listing Status of Deppon Logistics From Shanghai Stock Exchange

13 ian. 2026, 23:10 UTC

Achiziții, Fuziuni, Preluări

JD Logistics Makes Cash Offer to Buy Deppon Logistics Shares It Doesn't Already Own

13 ian. 2026, 23:03 UTC

Market Talk

Woodside's Sales Revenue Likely Fell 13% in 4Q -- Market Talk

13 ian. 2026, 21:50 UTC

Achiziții, Fuziuni, Preluări

Netflix Preparing to Make Warner Bid All-Cash -- WSJ

13 ian. 2026, 21:50 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Basic Materials Roundup: Market Talk

13 ian. 2026, 21:20 UTC

Achiziții, Fuziuni, Preluări

Versant Media: Katz Will Continue to Lead Day-To-Day Ops of FTN

13 ian. 2026, 21:20 UTC

Achiziții, Fuziuni, Preluări

Versant Media: Transaction Strengthens Distribution Footprint and Expands Free-To-Watch Portfolio >VSNT

13 ian. 2026, 21:20 UTC

Achiziții, Fuziuni, Preluări

Versant Media: Jonathan Katz, FTN's Founder, Has Joined VERSANT, Reporting to David Pietrycha >VSNT

13 ian. 2026, 21:15 UTC

Achiziții, Fuziuni, Preluări

VERSANT Completes Acquisition Of Free TV Networks >VSNT

13 ian. 2026, 21:08 UTC

Achiziții, Fuziuni, Preluări

Array Digital Infrastructure Declares Special Dividend of $10.25 >AD

13 ian. 2026, 20:39 UTC

Market Talk

Silver Settles at Another New High -- Market Talk

13 ian. 2026, 20:21 UTC

Market Talk

Oil Futures Extend Rally On Rising Iran Tensions -- Market Talk

13 ian. 2026, 20:17 UTC

Market Talk

U.S. Natural Gas Edges Up on Coming Weather -- Market Talk

13 ian. 2026, 19:08 UTC

Achiziții, Fuziuni, Preluări

Super Micro Computer Is an AI Winner. Sell the Stock Anyway, Goldman Sachs Says. -- Barrons.com

13 ian. 2026, 19:03 UTC

Câștiguri

Double-Digit Earnings Growth Could Continue. It Still Might Not Satisfy Investors. -- Barrons.com

13 ian. 2026, 18:50 UTC

Câștiguri

JPMorgan's Unusual Quarter Weighs on Shares. How Apple Plays a Role. -- Barrons.com

13 ian. 2026, 17:54 UTC

Market Talk

UnitedHealth Reaffirms 2025 Guidance After Senate Report -- Market Talk

13 ian. 2026, 17:50 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Global Equities Roundup: Market Talk

13 ian. 2026, 17:50 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Netflix Will Be a Winner No Matter How Warner Saga Ends -- Market Talk

13 ian. 2026, 17:49 UTC

Market Talk

Analysts Call For Potential Record Ethanol Output -- Market Talk

13 ian. 2026, 17:38 UTC

Market Talk

Merck CEO Sees $5B Market for Cidara's Flu Antiviral -- Market Talk

13 ian. 2026, 17:20 UTC

Market Talk

Financial Services Roundup: Market Talk

13 ian. 2026, 17:20 UTC

Market Talk

Health Care Roundup: Market Talk

13 ian. 2026, 17:20 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Basic Materials Roundup: Market Talk

13 ian. 2026, 17:19 UTC

Market Talk

Credit Cards Present Opportunity, Potential Obstacle for JPMorgan -- Market Talk

13 ian. 2026, 17:15 UTC

Market Talk

Merck CEO Sees Eventual Growth After Keytruda Exclusivity Expires -- Market Talk

Comparație

Modificare preț

TG Therapeutics Inc Așteptări

Obiectiv de preț

By TipRanks

42.62% sus

Prognoză pe 12 luni

Medie 43.5 USD  42.62%

Maxim 60 USD

Minim 15 USD

În baza a 4 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruTG Therapeutics Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

4 ratings

3

Cumpărare

0

Păstrare

1

Vânzare

Scor tehnic

By Trading Central

N/A / 34.86Suport & Rezistență

Termen scurt

Very Strong Bearish Evidence

Termen mediu

Bearish Evidence

Termen lung

Bullish Evidence

Sentiment

By Acuity

131 / 361 Clasament în Sănătate

Sentimentul știrilor

Evidențe de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre TG Therapeutics Inc

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.
help-icon Live chat